http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2013204315-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095 |
| filingDate | 2013-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05084886250253fcbc765bb9d39e60e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2b984447a9d94d7c3264ecba76fff61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3fd3ea98bfed8de1cbc10ddc92d819d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94c5d2abf422906eaa2f44b0444f72bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ee3dbfd8fc8d18bb9a7aaaec66bd9bb |
| publicationDate | 2013-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2013204315-A1 |
| titleOfInvention | Meningococcal vaccine formulations |
| abstract | A dual formulation for vaccines against Neisseria meningitidis serogroup B ('Men-B') comprises (i) an oil-in-water emulsion adjuvant and (ii) a Men-B immunogenic component in lyophilised form. The lyophilised Men-B antigens can be reconstituted into liquid adjuvanted form at the time of use 5 ready for administration to a patient. This formulation has been found to give excellent result in terms of both stability and immunogenicity. The lyophilised component can also include one or more conjugated saccharides from N.meningitidis in serogroups A, C, W135 and/or Y. |
| priorityDate | 2007-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 130.